Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma
Authors:
- 17 December 2015
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 37 (6) , 7507-7514
Abstract
Programmed cell death protein-1 (PD-1) inhibitor may be therapeutic in patients with relapsed or refractory classical Hodgkin’s lymphoma (cHL). This study examined the prognostic significance of PD-1 and two PD-1 ligands (PD-L1 and PD-L2) in uniformly treated cHL. Diagnostic tissues from 109 cHL patients treated with a doxorubicin, bleomycin, vinblastine, and dacarbazine regimen were evaluated retrospectively by immunohistochemical analysis of PD-L1, PD-L2, and PD-1 expressions. The median follow-up time was 4.91 years (range, 0.17–17.33 years). Thirteen patients (11 %) expressed PD-1 protein in the peritumoral microenvironment, which was associated with poor overall survival (OS) (P = 0.017). PD-L1 or PD-L2 expression was not associated with OS. There was no correlation between PD-L1 and PD-1 expression or between PD-L2 and PD-1 expression. Multivariate analysis identified PD-1 protein as an independent prognostic factor for OS (P = 0.019). Subgroup analysis according to the Ann Arbor stage of cHL showed that PD-1 protein expression had a prognostic value in limited-stage cHL (P = 0.048). PD-1 is an independent prognostic factor in cHL and may allow the identification of a subgroup of patients with limited-stage cHL who require more intensive therapy and who may benefit from anti-PD-1 agents.Keywords
Funding Information
- The Asan Institute for Life Sciences (2011-090)
This publication has 38 references indexed in Scilit:
- Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinomaMedical Oncology, 2015
- PDL1 expression is an independent prognostic factor in localized GISTOncoImmunology, 2015
- Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinomaAnnals of Oncology, 2015
- Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 BlockadeSeminars in Oncology, 2010
- Salvage Therapy for Hodgkin’s LymphomaThe Cancer Journal, 2009
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- PD-1 and PD-1 ligands: from discovery to clinical applicationInternational Immunology, 2007
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationJournal of Experimental Medicine, 2000
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998
- Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's diseaseAnnals of Oncology, 1995